{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:18:24Z","timestamp":1782587904710,"version":"3.54.5"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00213-019-05207-1","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T06:03:51Z","timestamp":1553321031000},"page":"989-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and \u03b12-adrenergic receptors"],"prefix":"10.1007","volume":"236","author":[{"given":"Adam L.","family":"Halberstadt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"key":"5207_CR1","unstructured":"Anonymous (2017) 2-Aminoindan reports. Available online: https:\/\/erowid.org\/experiences\/subs\/exp_2Aminoindan.shtml [Accessed: April 3, 2018]"},{"key":"5207_CR2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1471-4159.2010.06848.x","volume":"114","author":"AL Auclair","year":"2010","unstructured":"Auclair AL, Cathala A, Sarrazin F, Depoortere R, Piazza PV, Newman-Tancredi A, Spampinato U (2010) The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 114:1323\u20131332","journal-title":"J Neurochem"},{"key":"5207_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159\u2013163","journal-title":"Eur J Pharmacol"},{"key":"5207_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1476-5381.2012.02214.x","volume":"168","author":"CT Bauer","year":"2013","unstructured":"Bauer CT, Banks ML, Blough BE, Negus SS (2013) Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 168:850\u2013862","journal-title":"Br J Pharmacol"},{"key":"5207_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/npp.2015.260","volume":"41","author":"MH Baumann","year":"2016","unstructured":"Baumann MH, Volkow ND (2016) Abuse of new psychoactive substances: threats and solutions. Neuropsychopharmacology 41:663\u2013665","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/sj.npp.1300585","volume":"30","author":"MH Baumann","year":"2005","unstructured":"Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB (2005) N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or \u2018Ecstasy\u2019). Neuropsychopharmacology 30:550\u2013560","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/jpet.110.176271","volume":"337","author":"MH Baumann","year":"2011","unstructured":"Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337:218\u2013225","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR8","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/npp.2011.304","volume":"37","author":"MH Baumann","year":"2012","unstructured":"Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192\u20131203","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/npp.2012.204","volume":"38","author":"MH Baumann","year":"2013","unstructured":"Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38:552\u2013562","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/s41386-018-0013-0","volume":"43","author":"A Belmer","year":"2018","unstructured":"Belmer A, Quentin E, Diaz SL, Guiard BP, Fernandez SP, Doly S, Banas SM, Pitychoutis PM, Moutkine I, Muzerelle A, Tchenio A, Roumier A, Mameli M, Maroteaux L (2018) Positive regulation of raphe serotonin neurons by serotonin 2B receptors. Neuropsychopharmacology 43:1623\u20131632","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR11","doi-asserted-by":"crossref","unstructured":"Benedikt H (1893) VII. Das \u03b2-hydrindon und einige seiner Derivate. Justus Liebigs Ann Chem 275:351\u2013356","DOI":"10.1002\/jlac.18932750220"},{"key":"5207_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH, Roth BL, Hopkins AL (2012) Automated design of ligands to polypharmacological profiles. Nature 492:215\u2013220","journal-title":"Nature"},{"key":"5207_CR13","doi-asserted-by":"publisher","first-page":"16773","DOI":"10.1074\/jbc.M117.794081","volume":"292","author":"S Bhat","year":"2017","unstructured":"Bhat S, Hasenhuetl PS, Kasture A, El-Kasaby A, Baumann MH, Blough BE, Sucic S, Sandtner W, Freissmuth M (2017) Conformational state interactions provide clues to the pharmacochaperone potential of serotonin transporter partial substrates. J Biol Chem 292:16773\u201316786","journal-title":"J Biol Chem"},{"key":"5207_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/0091-3057(90)90538-S","volume":"37","author":"EJ Bilsky","year":"1990","unstructured":"Bilsky EJ, Hui YZ, Hubbell CL, Reid LD (1990) Methylenedioxymethamphetamine's capacity to establish place preferences and modify intake of an alcoholic beverage. Pharmacol Biochem Behav 37:633\u2013638","journal-title":"Pharmacol Biochem Behav"},{"key":"5207_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/B978-0-12-415816-0.00011-0","volume-title":"Novel psychoactive substances: classification, pharmacology and toxicology","author":"SD Brandt","year":"2013","unstructured":"Brandt SD, Braithwaite RA, Evans-Brown M, Kicman AT (2013) Aminoindane analogues. In: Dargan PI, Wood DM (eds) Novel psychoactive substances: classification, pharmacology and toxicology. Academic Press, Tokyo, pp 261\u2013283"},{"key":"5207_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugpo.2017.03.006","volume":"44","author":"TM Brunt","year":"2017","unstructured":"Brunt TM, Atkinson AM, Nefau T, Martinez M, Lahaie E, Malzcewski A, Pazitny M, Belackova V, Brandt SD (2017) Online test purchased new psychoactive substances in 5 different European countries: a snapshot study of chemical composition and price. Int J Drug Policy 44:105\u2013114","journal-title":"Int J Drug Policy"},{"key":"5207_CR17","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099\u20133108","journal-title":"Biochem Pharmacol"},{"key":"5207_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/hup.2298","volume":"28","author":"JM Corkery","year":"2013","unstructured":"Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH (2013) MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; \u2018sparkle\u2019; \u2018mindy\u2019) toxicity: a brief overview and update. Hum Psychopharmacol 28:345\u2013355","journal-title":"Hum Psychopharmacol"},{"key":"5207_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2012.11.008","volume":"699","author":"NV Cozzi","year":"2013","unstructured":"Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699:180\u2013187","journal-title":"Eur J Pharmacol"},{"key":"5207_CR20","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1523\/JNEUROSCI.5723-07.2008","volume":"28","author":"S Doly","year":"2008","unstructured":"Doly S, Valjent E, Setola V, Callebert J, Herve D, Launay JM, Maroteaux L (2008) Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J Neurosci 28:2933\u20132940","journal-title":"J Neurosci"},{"key":"5207_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007952","volume":"4","author":"S Doly","year":"2009","unstructured":"Doly S, Bertran-Gonzalez J, Callebert J, Bruneau A, Banas SM, Belmer A, Boutourlinsky K, Herve D, Launay JM, Maroteaux L (2009) Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One 4:e7952","journal-title":"PLoS One"},{"key":"5207_CR22","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","volume":"100","author":"S Droogmans","year":"2007","unstructured":"Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G (2007) Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100:1442\u20131445","journal-title":"Am J Cardiol"},{"key":"5207_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.forsciint.2014.04.017","volume":"243","author":"S Elliott","year":"2014","unstructured":"Elliott S, Evans J (2014) A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243:55\u201360","journal-title":"Forensic Sci Int"},{"key":"5207_CR24","volume-title":"EMCDDA-Europol 2006 annual report on the implementation of council decision 2005\/387\/JHA","author":"EMCDDA","year":"2007","unstructured":"EMCDDA (2007) EMCDDA-Europol 2006 annual report on the implementation of council decision 2005\/387\/JHA. Publications Office of the European Union, Lisbon"},{"key":"5207_CR25","volume-title":"EMCDDA-Europol 2010 annual report on the implementation of council decision 2005\/387\/JHA","author":"EMCDDA","year":"2011","unstructured":"EMCDDA (2011) EMCDDA-Europol 2010 annual report on the implementation of council decision 2005\/387\/JHA. Publications Office of the European Union, Lisbon"},{"key":"5207_CR26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1523\/JNEUROSCI.2796-07.2008","volume":"28","author":"K Erreger","year":"2008","unstructured":"Erreger K, Grewer C, Javitch JA, Galli A (2008) Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function. J Neurosci 28:976\u2013989","journal-title":"J Neurosci"},{"key":"5207_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/jpet.116.236349","volume":"360","author":"AJ Eshleman","year":"2017","unstructured":"Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-activity relationships of substituted cathinones, with transporter binding, uptake, and release. J Pharmacol Exp Ther 360:33\u201347","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"M Farre","year":"2007","unstructured":"Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O\u2019Mathuna B, Segura M, de la Torre R (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954\u2013962","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR29","first-page":"75","volume":"57","author":"LW Fitzgerald","year":"2000","unstructured":"Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75\u201381","journal-title":"Mol Pharmacol"},{"key":"5207_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0376-8716(91)90052-Z","volume":"28","author":"RW Foltin","year":"1991","unstructured":"Foltin RW, Fischman MW (1991) Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28:3\u201348","journal-title":"Drug Alcohol Depend"},{"key":"5207_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0896-6273(00)80418-3","volume":"19","author":"EA Fon","year":"1997","unstructured":"Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271\u20131283","journal-title":"Neuron"},{"key":"5207_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10652","volume":"7","author":"Z Freyberg","year":"2016","unstructured":"Freyberg Z, Sonders MS, Aguilar JI, Hiranita T, Karam CS, Flores J, Pizzo AB, Zhang Y, Farino ZJ, Chen A, Martin CA, Kopajtic TA, Fei H, Hu G, Lin YY, Mosharov EV, McCabe BD, Freyberg R, Wimalasena K, Hsin LW, Sames D, Krantz DE, Katz JL, Sulzer D, Javitch JA (2016) Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun 7:10652","journal-title":"Nat Commun"},{"key":"5207_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1378\/chest.118.5.1496","volume":"118","author":"SP Gaine","year":"2000","unstructured":"Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118:1496\u20131497","journal-title":"Chest"},{"key":"5207_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00213-009-1501-z","volume":"204","author":"MB Gatch","year":"2009","unstructured":"Gatch MB, Rutledge MA, Carbonaro T, Forster MJ (2009) Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology 204:715\u2013724","journal-title":"Psychopharmacology"},{"key":"5207_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FBP.0000000000000237","volume":"27","author":"MB Gatch","year":"2016","unstructured":"Gatch MB, Dolan SB, Forster MJ (2016) Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents. Behav Pharmacol 27:497\u2013505","journal-title":"Behav Pharmacol"},{"key":"5207_CR36","first-page":"43","volume":"94","author":"RA Glennon","year":"1989","unstructured":"Glennon RA (1989) Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships. NIDA Res Monogr 94:43\u201367","journal-title":"NIDA Res Monogr"},{"key":"5207_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0091-3057(84)80071-4","volume":"21","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Young R, Hauck AE, McKenney JD (1984) Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol Biochem Behav 21:895\u2013901","journal-title":"Pharmacol Biochem Behav"},{"key":"5207_CR38","unstructured":"Golan E (2016) Alcoholic beverage substitute. International patent application No. WO. 2016\/092547"},{"key":"5207_CR39","first-page":"79","volume":"96","author":"EG Gray","year":"1962","unstructured":"Gray EG, Whittaker VP (1962) The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J Anat 96:79\u201388","journal-title":"J Anat"},{"key":"5207_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt1975185part1563","volume":"18","author":"JD Griffith","year":"1975","unstructured":"Griffith JD, Nutt JG, Jasinski DR (1975) A comparison of fenfluramine and amphetamine in man. Clin Pharmacol Ther 18:563\u2013570","journal-title":"Clin Pharmacol Ther"},{"key":"5207_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/7854_2016_64","volume":"32","author":"AL Halberstadt","year":"2017","unstructured":"Halberstadt AL (2017) Pharmacology and toxicology of N-benzylphenethylamine (\u201cNBOMe\u201d) hallucinogens. Curr Top Behav Neurosci 32:283\u2013311","journal-title":"Curr Top Behav Neurosci"},{"key":"5207_CR42","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/mol.109.058057","volume":"76","author":"XP Huang","year":"2009","unstructured":"Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL (2009) Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 76:710\u2013722","journal-title":"Mol Pharmacol"},{"key":"5207_CR43","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1373\/clinchem.2017.274662","volume":"63","author":"MA Huestis","year":"2017","unstructured":"Huestis MA, Brandt SD, Rana S, Auwarter V, Baumann MH (2017) Impact of novel psychoactive substances on clinical and forensic toxicology and global public health. Clin Chem 63:1564\u20131569","journal-title":"Clin Chem"},{"key":"5207_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.euroneuro.2015.12.010","volume":"26","author":"BA Hutsell","year":"2016","unstructured":"Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, Negus SS (2016) Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol 26:288\u2013297","journal-title":"Eur Neuropsychopharmacol"},{"key":"5207_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther 90:246\u2013255","journal-title":"Clin Pharmacol Ther"},{"key":"5207_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2012.12.006","volume":"700","author":"L Iversen","year":"2013","unstructured":"Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700:147\u2013151","journal-title":"Eur J Pharmacol"},{"key":"5207_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00213-010-1911-y","volume":"211","author":"RK Jan","year":"2010","unstructured":"Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR (2010) Determining the subjective effects of TFMPP in human males. Psychopharmacology 211:347\u2013353","journal-title":"Psychopharmacology"},{"key":"5207_CR48","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00414-012-0671-0","volume":"126","author":"SS Johansen","year":"2012","unstructured":"Johansen SS, Hansen TM (2012) Isomers of fluoroamphetamines detected in forensic cases in Denmark. Int J Legal Med 126:541\u2013547","journal-title":"Int J Legal Med"},{"key":"5207_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0014-2999(91)90659-E","volume":"200","author":"MP Johnson","year":"1991","unstructured":"Johnson MP, Conarty PF, Nichols DE (1991a) [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200:9\u201316","journal-title":"Eur J Pharmacol"},{"key":"5207_CR50","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1021\/jm00109a020","volume":"34","author":"MP Johnson","year":"1991","unstructured":"Johnson MP, Frescas SP, Oberlender R, Nichols DE (1991b) Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J Med Chem 34:1662\u20131668","journal-title":"J Med Chem"},{"key":"5207_CR51","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nm764","volume":"8","author":"JM Launay","year":"2002","unstructured":"Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129\u20131135","journal-title":"Nat Med"},{"key":"5207_CR52","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513\u2013521","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/00008571-200412000-00003","volume":"14","author":"Z Lin","year":"2004","unstructured":"Lin Z, Walther D, Yu XY, Drgon T, Uhl GR (2004) The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics 14:805\u2013811","journal-title":"Pharmacogenetics"},{"key":"5207_CR54","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/add.12932","volume":"110","author":"F Linsen","year":"2015","unstructured":"Linsen F, Koning RP, van Laar M, Niesink RJ, Koeter MW, Brunt TM (2015) 4-Fluoroamphetamine in the Netherlands: more than a one-night stand. Addiction 110:1138\u20131143","journal-title":"Addiction"},{"key":"5207_CR55","doi-asserted-by":"crossref","unstructured":"Luethi D, Kolaczynska KE, Docci L, Krahenbuhl S, Hoener MC, Liechti ME (2018) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134:4\u201312","DOI":"10.1016\/j.neuropharm.2017.07.026"},{"key":"5207_CR56","first-page":"412","volume":"6","author":"L Malmusi","year":"1996","unstructured":"Malmusi L, Dukat M, Young R, Teitler M, Darmani NA, Ahmad B, Smith C, Glennon RA (1996) 1,2,3,4-Tetrahydroisoquinoline and related analogs of the phenylalkylamine designer drug MDMA. Med Chem Res 6:412\u2013426","journal-title":"Med Chem Res"},{"key":"5207_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(94)90051-5","volume":"258","author":"D Marona-Lewicka","year":"1994","unstructured":"Marona-Lewicka D, Nichols DE (1994) Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur J Pharmacol 258:1\u201313","journal-title":"Eur J Pharmacol"},{"key":"5207_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s002130050646","volume":"138","author":"D Marona-Lewicka","year":"1998","unstructured":"Marona-Lewicka D, Nichols DE (1998) Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 138:67\u201375","journal-title":"Psychopharmacology"},{"key":"5207_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0091-3057(95)00205-7","volume":"53","author":"D Marona-Lewicka","year":"1996","unstructured":"Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1996) Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 53:99\u2013105","journal-title":"Pharmacol Biochem Behav"},{"key":"5207_CR60","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.075","volume":"559","author":"F Nagai","year":"2007","unstructured":"Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132\u2013137","journal-title":"Eur J Pharmacol"},{"key":"5207_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1021\/jm00164a037","volume":"33","author":"DE Nichols","year":"1990","unstructured":"Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (1990) Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J Med Chem 33:703\u2013710","journal-title":"J Med Chem"},{"key":"5207_CR62","first-page":"1098","volume":"255","author":"R Oberlender","year":"1990","unstructured":"Oberlender R, Nichols DE (1990) (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. J Pharmacol Exp Ther 255:1098\u20131106","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0091-3057(91)90017-V","volume":"38","author":"R Oberlender","year":"1991","unstructured":"Oberlender R, Nichols DE (1991) Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol Biochem Behav 38:581\u2013586","journal-title":"Pharmacol Biochem Behav"},{"key":"5207_CR64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/jpet.106.103622","volume":"319","author":"JS Partilla","year":"2006","unstructured":"Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319:237\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR65","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neubiorev.2005.04.016","volume":"30","author":"RC Pierce","year":"2006","unstructured":"Pierce RC, Kumaresan V (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215\u2013238","journal-title":"Neurosci Biobehav Rev"},{"key":"5207_CR66","unstructured":"Richter H, Schenck M (1956) Verfahren zur Herstellung von analgetisch wirksamen 2-Aminoindanverbindungen. German Patent No. DE952441"},{"key":"5207_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6\u20139","journal-title":"N Engl J Med"},{"key":"5207_CR68","unstructured":"Roth BL (2013) National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) Assay Protocol Book, Version II. Available online: https:\/\/pdspdb.unc.edu\/pdspWeb\/content\/PDSP%20Protocols%20II%202013-03-28.pdf [Accessed: 06 May 2017]"},{"key":"5207_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1196\/annals.1369.064","volume":"1074","author":"RB Rothman","year":"2006","unstructured":"Rothman RB, Baumann MH (2006a) Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 1074:245\u2013260","journal-title":"Ann N Y Acad Sci"},{"key":"5207_CR70","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/156802606778249766","volume":"6","author":"RB Rothman","year":"2006","unstructured":"Rothman RB, Baumann MH (2006b) Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem 6:1845\u20131859","journal-title":"Curr Top Med Chem"},{"key":"5207_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1161\/01.CIR.100.8.869","volume":"100","author":"RB Rothman","year":"1999","unstructured":"Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100:869\u2013875","journal-title":"Circulation"},{"key":"5207_CR72","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836\u20132841","journal-title":"Circulation"},{"key":"5207_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32\u201341","journal-title":"Synapse"},{"key":"5207_CR74","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1124\/jpet.103.049684","volume":"305","author":"RB Rothman","year":"2003","unstructured":"Rothman RB, Clark RD, Partilla JS, Baumann MH (2003) (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305:1191\u20131199","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR75","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0005-2728(93)90109-S","volume":"1144","author":"G Rudnick","year":"1993","unstructured":"Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144:249\u2013263","journal-title":"Biochim Biophys Acta"},{"key":"5207_CR76","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1124\/mol.115.101394","volume":"89","author":"W Sandtner","year":"2016","unstructured":"Sandtner W, Stockner T, Hasenhuetl PS, Partilla JS, Seddik A, Zhang YW, Cao J, Holy M, Steinkellner T, Rudnick G, Baumann MH, Ecker GF, Newman AH, Sitte HH (2016) Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol Pharmacol 89:165\u2013175","journal-title":"Mol Pharmacol"},{"key":"5207_CR77","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/0091-3057(86)90480-6","volume":"24","author":"MD Schechter","year":"1986","unstructured":"Schechter MD (1986) Discriminative profile of MDMA. Pharmacol Biochem Behav 24:1533\u20131537","journal-title":"Pharmacol Biochem Behav"},{"key":"5207_CR78","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00213-015-4057-0","volume":"233","author":"CW Schindler","year":"2016","unstructured":"Schindler CW, Thorndike EB, Goldberg SR, Lehner KR, Cozzi NV, Brandt SD, Baumann MH (2016) Reinforcing and neurochemical effects of the \"bath salts\" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology 233:1981\u20131990","journal-title":"Psychopharmacology"},{"key":"5207_CR79","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223\u20131229","journal-title":"Mol Pharmacol"},{"key":"5207_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.taap.2017.01.018","volume":"319","author":"JA Shimshoni","year":"2017","unstructured":"Shimshoni JA, Winkler I, Edery N, Golan E, van Wettum R, Nutt D (2017) Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): binge mitigating agent in development. Toxicol Appl Pharmacol 319:59\u201368","journal-title":"Toxicol Appl Pharmacol"},{"key":"5207_CR81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.taap.2018.02.009","volume":"343","author":"JA Shimshoni","year":"2018","unstructured":"Shimshoni JA, Sobol E, Golan E, Ben Ari Y, Gal O (2018) Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): a new binge-mitigating agent. Toxicol Appl Pharmacol 343:29\u201339","journal-title":"Toxicol Appl Pharmacol"},{"key":"5207_CR82","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"LD Simmler","year":"2013","unstructured":"Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458\u2013470","journal-title":"Br J Pharmacol"},{"key":"5207_CR83","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neuropharm.2013.11.008","volume":"79","author":"LD Simmler","year":"2014","unstructured":"Simmler LD, Rickli A, Hoener MC, Liechti ME (2014a) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152\u2013160","journal-title":"Neuropharmacology"},{"key":"5207_CR84","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bcp.2014.01.024","volume":"88","author":"LD Simmler","year":"2014","unstructured":"Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014b) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88:237\u2013244","journal-title":"Biochem Pharmacol"},{"key":"5207_CR85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41\u201350","journal-title":"Trends Pharmacol Sci"},{"key":"5207_CR86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0262-4079(15)60011-2","volume":"225","author":"M Slezak","year":"2015","unstructured":"Slezak M (2015) A not-so-bitter pill. New Scientist 225:8\u20139","journal-title":"New Scientist"},{"key":"5207_CR87","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3109\/00952990903383961","volume":"35","author":"M Sofuoglu","year":"2009","unstructured":"Sofuoglu M, Poling J, Hill K, Kosten T (2009) Atomoxetine attenuates dextroamphetamine effects in humans. Am J Drug Alcohol Abuse 35:412\u2013416","journal-title":"Am J Drug Alcohol Abuse"},{"key":"5207_CR88","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/npp.2017.98","volume":"42","author":"E Solis Jr","year":"2017","unstructured":"Solis E Jr, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, Eltit JM, Glennon RA, Negus SS, Baumann MH (2017) N-alkylated analogs of 4-Methylamphetamine (4-MA) differentially affect monoamine transporters and abuse liability. Neuropsychopharmacology 42:1950\u20131961","journal-title":"Neuropsychopharmacology"},{"key":"5207_CR89","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1523\/JNEUROSCI.15-05-04102.1995","volume":"15","author":"D Sulzer","year":"1995","unstructured":"Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102\u20134108","journal-title":"J Neurosci"},{"key":"5207_CR90","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","volume":"75","author":"D Sulzer","year":"2005","unstructured":"Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406\u2013433","journal-title":"Prog Neurobiol"},{"key":"5207_CR91","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2007","unstructured":"Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189:565\u2013573","journal-title":"Psychopharmacology"},{"key":"5207_CR92","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1038\/tp.2015.170","volume":"5","author":"R Tikkanen","year":"2015","unstructured":"Tikkanen R, Tiihonen J, Rautiainen MR, Paunio T, Bevilacqua L, Panarsky R, Goldman D, Virkkunen M (2015) Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon. Transl Psychiatry 5:e681","journal-title":"Transl Psychiatry"},{"key":"5207_CR93","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1124\/jpet.104.080101","volume":"313","author":"S Wee","year":"2005","unstructured":"Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848\u2013854","journal-title":"J Pharmacol Exp Ther"},{"key":"5207_CR94","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1126\/science.1252884","volume":"344","author":"BG Wilhelm","year":"2014","unstructured":"Wilhelm BG, Mandad S, Truckenbrodt S, Krohnert K, Schafer C, Rammner B, Koo SJ, Classen GA, Krauss M, Haucke V, Urlaub H, Rizzoli SO (2014) Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344:1023\u20131028","journal-title":"Science"},{"key":"5207_CR95","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0959-4388(96)80079-1","volume":"6","author":"RA Wise","year":"1996","unstructured":"Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6:243\u2013251","journal-title":"Curr Opin Neurobiol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05207-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T02:27:31Z","timestamp":1721096851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05207-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5207"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05207-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal use procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Care and Use Committee of the Intramural Research Program of the National Institute on Drug Abuse (Baltimore, MD, USA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}